ライフサイエンスコーパス: hydroxyphenyl

1 Bisphenol A, bisphenol AF, and 2-2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (group 1) strongly

2 heylene-1,2-diamine (13) and (+/-)-2,3-di-(2-hydroxyphenyl)-1,2-dihydroquinoxaline (17), respectively

3 1-phenylbut-1-en-2-yl)phenol (7) > E 4-(1-(4-hydroxyphenyl)-1-phenylbut-1-en-2-yl)phenol (6) > Z(4-(1

4 is(4-hydroxyphenyl)but-1-ene (3) > Z 4-(1-(4-hydroxyphenyl)-1-phenylbut-1-en-2-yl)phenol (7) > E 4-(1

5 cells 2-(2-fluoro-4-hydroxyphenyl)-3,5-bis(4-hydroxyphenyl)-1-propyl-1H-pyrrole 8b (EC(50) = 0.12 nM)

6 lls was determined for 2,3,5-tris(2-fluoro-4-hydroxyphenyl)-1-propyl-1H-pyrrole 8m (EC(50) = 23 nM),

7 The probe, 3-(2-hydroxyphenyl)-1-pyrenyl-2-propenone (PA-1) was synthesi

8 2-Hydroxy-8-(4-hydroxyphenyl)-1H-phenalen-1-one (1), the first reported

9 2,6-dimethyl-3,5,7-trihydroxy-7-(3'-amino-5'-hydroxyphenyl)-2,4-heptadieno ic acid (P8/1-OG), an inte

10 Synthesis of few 4(5)-(2-hydroxyphenyl)-2,5(4)-substituted imidazoles, which are

11 We previously identified (E)-2,4-bis(p-hydroxyphenyl)-2-butenal (BHPB), a tyrosine-fructose Mai

12 e)), 5, and [Re(O)(NAr)(hoz)2+] (hoz = 2-(2'-hydroxyphenyl)-2-oxazoline) (Ar = 2,4,6,-(Me)C(6)H(2); 4

13 The synthesis employed 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene (1) as a useful buildin

14 er of potency as followed: E2 > 1,1-bis(4,4'-hydroxyphenyl)-2-phenylbut-1-ene (15) > 1,1,2-tris(4-hyd

15 The resultant 4-butyl-4-hydroxy-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione (4-OH-OPB)

16 order formation of (Z)-2-(chloromethyl)-3-(2-hydroxyphenyl)-2-propenoic acid.

17 10 compounds, (1R,5R,9S)-(-)-9-hydroxy-5-(3-hydroxyphenyl-2-phenylethyl-2-azabicyclo[3.3.1]nona ne (

18 The retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) grea

19 6-[3-(1-admantyl)]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) is

20 the synthetic retinoid, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437), ef

21 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid increased R

22 proapoptotic retinoids 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid or N-(4-hyd

23 inducer AHPN {retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid} acts by re

24 The retinoid 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) and i

25 hich was derived from 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN), and

26 thetic retinoid-related 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN)/CD437

27 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437/AHPN)

28 sis of structurally rigid N-substituted-6-(3-hydroxyphenyl)3-azabicyclo[3.1.0]hexane and 3-methyl-4-(

29 (3R)-7-Hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-pipe ridinyl]methyl]-2-met

30 r: RTI-5989-212[(3R)-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidin yl]methyl}-(2-me

31 9-97 [(3S)-7-hydroxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-(2-me

32 -194 [(3R)-7-hydroxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-(2-me

33 and (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-2-met

34 ies, (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-2-met

35 (3 R)-7-hydroxy- N-((1 S)-1-{[(3 R,4 R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-meth

36 -240 [(3R)-7-hydroxy-N-[(1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl ]methyl}-(2-me

37 and (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl ]methyl}-(2-me

38 )-7-Hydroxy- N-[(1 S,2 S)-1-{[(3 R,4 R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-2-meth

39 d (3R)-7-hydroxy-N-[(1S,2S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidine- 1-yl]methyl}-2-me

40 , while in U2-OS/ERalpha cells 2-(2-fluoro-4-hydroxyphenyl)-3,5-bis(4-hydroxyphenyl)-1-propyl-1H-pyrr

41 ation and utilization of novel modified N-(4-hydroxyphenyl)-3,5-dinitrobenzamide-FePt/CNTs carbon pas

42 These studies led to N-[(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl}-2-methylpr

43 Its analogue, (E)-4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-(3'-acetamidopropyloxy)cinnami c acid (

44 nyl}-1H-tetrazole, 5-{4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorobenzylidene}thiazolidine-2,4-dio

45 oid-related molecule 4-[3-Cl-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) activat

46 (E)-4-[3'-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces

47 (E)-4-[3-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces

48 h AHPN/CD437 analog (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces

49 that the novel compound 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC), induce

50 r receptor ligand (E)-4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC), which

51 c acid (CD437/AHPN) and 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC/MM002) a

52 be a novel compound (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC/MM002) t

53 comparable to that of 4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid.

54 4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorophenyltetrazole, (2E)-5-{2-[3'-(1

55 Bisphenol A, bisphenol S, and 4-hydroxyphenyl 4-isoprooxyphenylsulfone (BPSIP) in urine

56 the BPA alternatives bisphenol S (BPS) and 4-hydroxyphenyl 4-isoprooxyphenylsulfone (BPSIP).

57 into a C=S group provided 5,7-dihydroxy-3-(4-hydroxyphenyl)-4(3H)-quinazolinethione (1ba), which acts

58 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4(3H)-quinazolinone (1aa) acts as an agon

59 The well known MIF inhibitor (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

60 essed the therapeutic efficacy of (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

61 es with hydroxyphenylpyruvate and (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

62 ctivity; a lead molecule, "ISO-1 ((S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

63 Treatment with the MIF antagonist (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methy

64 )3-azabicyclo[3.1.0]hexane and 3-methyl-4-(3-hydroxyphenyl)-4-azabicyclo[4.1.0]heptanes.

65 udy, we identified (-)-N-[(1R,4S,5S,7R)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-aza bicyclo

66 acetamide analogue (+)-N-[(1S,4R,5R,7S)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-aza bicyclo

67 recently reported the discovery of (+)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[

68 This compound, (+)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[

69 M, raloxifene, the benzopyran SERM, (S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]ph

70 f iron chelators, three (S)-4,5-dihydro-2-(2-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid (DADFT

71 desazadesferrithiocin, (S)-4,5-dihydro-2-(2-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid, on th

72 revented by the ERalpha antagonist 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol

73 approved potentiator N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

74 the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

75 e lesser peak was identified as 4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid glucoside (AHBG).

76 l meroterpenoids, namely, 2-(tetrahydro-5-(4-hydroxyphenyl)-4-pentylfuran-3-yl)-ethyl-4-hydroxybenzoa

77 and ER-beta-specific agonists [1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) and 2,3-bis(4-

78 the selective ERalpha agonist, 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) as well as by

79 ERalpha selective agonist PPT (1,3,5-tris (4-hydroxyphenyl)-4-propyl-1H-pyrazole) and the ERbeta sele

80 acid (DADFT) and three (S)-4,5-dihydro-2-(2-hydroxyphenyl)-4-thiazolecarboxylic acid (DADMDFT) analo

81 Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) has been previousl

82 Compound 2 (3,6-dihydroxy-2-(3-hydroxyphenyl)-4H-chromen-4-one) was selected for pharma

83 inctive ligand in this series, 2-phenyl-3-(4-hydroxyphenyl)-5,7-bis(trifluoromethyl)-pyrazolo[1,5-a]p

84 ein kinase inhibitor 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB 202190) an

85 inase inhibitor, and 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole.

86 ation with SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole], a p38 inhibit

87 inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole].

88 inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole].

89 inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole]; the effect of

90 and proapoptotic (E)-6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-5-chloronaphthalenecarboxylic acid (5-Cl-

91 estigate the mode of binding of 2-amino-4-(4-hydroxyphenyl)- 6-(1H-imidazol-2-ylmethylsulfanyl)pyridi

92 ed by formation of the water-insoluble 2-(2'-hydroxyphenyl)-6-[(125)I]iodo-4-(3H)-quinazolinone ((125

93 1-(3'-Formyl-4'-hydroxyphenyl)-8-(9'-anthryl)naphthalene (1) was prepare

94 N-[4a-(3-Hydroxyphenyl)-8a-methyl-2-(3-phenylpropyl)octahydroisoq

95 N-Substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines (6a-g) we

96 ne ((1R,5S)-(+)-14), and (1R,5S,9R)-(-)-5-(3-hydroxyphenyl)-9-methyl-2-phenethyl-2-azabicyclo[3.3.1]n

97 ona ne ((1R,5R,9S)-(-)-10), (1R,5S)-(+)-5-(3-hydroxyphenyl)-9-methylene-2-phenethyl-2-azabicyclo[3.3.

98 ds were notably high in their 2-hydroxy-N-(2-hydroxyphenyl) acetamide (HHPAA) concentration (40-48mic

99 enzoxazin-3-one (HBOA-d4) and 2-hydroxy-N-(2-hydroxyphenyl) acetamide (HHPAA-d4) were synthesized, to

100 by organohalide respiration using 3-chloro-4-hydroxyphenyl acetate (Cl-OHPA) as an electron acceptor.

101 rbamoylmethylene linked promoiety containing hydroxyphenyl acetic acid (HPA) derived ester and phosph

102 dministration of (R,S)-2-Amino-2-(2-chloro-5-hydroxyphenyl)acetic acid sodium salt (CHPG) an mGluR5 a

103 ors [10 microg of (RS)-2-amino-2-(2-chloro-5-hydroxyphenyl)acetic acid sodium salt] enhanced the disc

104 helated by transferrin, ethylenediamine-di(o-hydroxyphenyl-acetic acid), or other iron-chelating comp

105 ring-opening of activated aziridines with 2-hydroxyphenyl acrylates and 2-aminophenyl acrylate, resp

106 sized from unlabeled (or [(2)H]-labeled) (4'-hydroxyphenyl)acrylic acids by reduction with D2 (or H2)

107 xperiment indicate that the bond between the hydroxyphenyl and hydroxycyclohexyl rings is oriented pe

108 hat the binding tests homologize: both the 3-hydroxyphenyl and the 5-hydroxy-3-pyridyl ether of N-met

109 Diverse meso-aminophenyl-, hydroxyphenyl-, and phenyl-substituted heptamethine cyan

110 pair responses, the transport inhibitor N-(4-hydroxyphenyl)-arachidonamide (AM404) and the FAAH inhib

111 s and astrocytes, which is inhibited by N-(4-hydroxyphenyl)-arachidonamide (AM404).

112 scovered that the meta isomer of AM404, N-(3-hydroxyphenyl)arachidonoylamide (3-HPAA), is a substrate

113 N-(4-Hydroxyphenyl)arachidonoylamide (AM404) is an inhibitor

114 In general, arvanil, olvanil, and N-(4-hydroxyphenyl)arachidonylamide (AM404) have been charact

115 inhibited in a dose-dependent manner by N-(4-hydroxyphenyl)arachidonylamide (AM404).

116 previous work, several 1-alkyl-2,3,5-tris(4-hydroxyphenyl)aryl-1H-pyrroles with chlorine or fluorine

117 ormation of adducts between photoactivated 3-hydroxyphenyl azide and RNA.

118 RNA-tethered 3-hydroxyphenyl azide cross-linking in aqueous buffer can

119 ive species present upon the photolysis of 3-hydroxyphenyl azide in aqueous solution.

120 The intermediate produced by photolysis of 3-hydroxyphenyl azide is much more reactive than the inter

121 n experiments show that photolysis of free 3-hydroxyphenyl azide releases (in <or=20 ns) either a ket

122 produced upon photolysis of phenyl azide, 3-hydroxyphenyl azide, 3-methoxyphenyl azide, and 3-nitrop

123 ures--using a library of 56 N-(3,5-dibromo-4-hydroxyphenyl)benzamides.

124 nversion of dibenzothiophene sulfone to 2-(2-hydroxyphenyl)-benzenesulfinic acid, is catalyzed by a u

125 -phenylenediamine to give 2-(3,5-dimethoxy-4-hydroxyphenyl)benzimidazole coupled with the reduction o

126 yrene resin was reacted with 4-(5'-formyl-2'-hydroxyphenyl)benzoic acid and 4-(5'-formyl-2'-hydroxyph

127 2-(2'-Hydroxyphenyl)benzoxazole (HBO) derivatives represent an

128 , the rotational energy barrier of 2- (2',6'-hydroxyphenyl)benzoxazole is determined to be 10.5 kcal/

129 NR2B antagonist, Ro25-6981 [R-(R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

130 ctive antagonist Ro25-6981 [R-(R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

131 nimodipine, or Ro 25-6981 [R-(R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

132 receptors using RO25-6981 [R-(R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

133 2B receptor ifenprodil and R-(R, S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine

134 yl)phenol (6) > Z(4-(1-(4-ethoxyphenyl)-1-(4-hydroxyphenyl)but-1-en-2-yl)phenol (12) > 4-OHTAM.

135 henyl)-2-phenylbut-1-ene (15) > 1,1,2-tris(4-hydroxyphenyl)but-1-ene (3) > Z 4-(1-(4-hydroxyphenyl)-1

136 phenylethylidene)bisphenol (BPAP), 2,2-bis(4-hydroxyphenyl)butane (BPB), 4,4'-dihydroxydiphenylmethan

137 3)O(2), using the photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC).

138 9(11)-en-24-one; 4-(2Z)-2-decen-1-yl-5-[1-(4-hydroxyphenyl)decyl]-1,2-benzenediol; 8-[(2E)-3,7-dimeth

139 iscyclohexano-fused Mn(III) complexes of bis(hydroxyphenyl)dipyrromethenes, 4a-c, as potent and orall

140 rystal X-ray analysis of 6a shows that the 3-hydroxyphenyl equatorial conformation is favored in the

141 The 3-hydroxyphenyl equatorial conformation is responsible for

142 mbled monolayers switches a nonelectroactive hydroxyphenyl ester to an electroactive hydroquinone, pr

143 nfirmed using a model compound, 1-(2-amino-3-hydroxyphenyl)ethan-1-one, which is an aminophenol lacki

144 ogue of this ligand (2) in 9 steps from 2-(4-hydroxyphenyl)ethanol and in 34% overall yield.

145 phenone); and triclosan (2,4,4'-trichloro-2'-hydroxyphenyl ether).

146 The resulting 3-pyridyl and m-hydroxyphenyl ethers have high alpha4beta2 affinity and

147 iomimetic synthesis of 3,4-DHPEA-EDA [2-(3,4-hydroxyphenyl) ethyl (3S,4E)-4-formyl-3-(2-oxoethyl)hex-

148 abeled using (111)In-DOTA or (125)I-iodo-((4-hydroxyphenyl)ethyl) maleimide (HPEM).

149 somer (S)-N(1)-methyl-2-[2'-(3''-methoxy-4''-hydroxyphenyl)ethyl]-1,2,3,4-tetrahydroqui noline is rep

150 ne to (S)-N(1)-methyl-2-[2'-(3''-methoxy-4''-hydroxyphenyl)ethyl]-1,2,3,4-tetrahydroqui noline.

151 peptide thioesters containing one or more p-(hydroxyphenyl)glycine (pHPG) residues and L-serine, some

152 During this process, N-(4-hydroxyphenyl)glycine served as a source of N doping and

153 that structural rigid compounds having the 3-hydroxyphenyl group locked in the piperidine equatorial

154 nt of the 3-hydroxyl substituent of the 4-(3-hydroxyphenyl) group of JDTic with a H, F, or Cl substit

155 to produce the three primary lignin units: p-hydroxyphenyl, guaiacyl, and syringyl, respectively, whe

156 , resulting in a lignin polymer containing p-hydroxyphenyl (H), catechyl (C) and guaiacyl (G) units.

157 t secondary cell walls and is derived from p-hydroxyphenyl (H), guaiacyl (G), and syringyl (S) monoli

158 oic acid (Ahppa) and the novel 2-amino-6-(4'-hydroxyphenyl)hexanoic acid (Ahpha), respectively.

159 al modification performed on a 4-methyl-4-(4-hydroxyphenyl)hydantoin series is described which result

160 oxy-4'-methoxyphenyl)hydracrylic acid, 3-(3'-hydroxyphenyl)hydracrylic acid, 3'-methoxy-4'-hydroxyphe

161 The C24-N-(4-p-hydroxyphenyl)imidazol-5-yl constitution found in amaran

162 oles A, C, and D is replaced by a C24-O-(4-p-hydroxyphenyl)imidazole-2-carboxylate motif in amaranzol

163 (+)-4-[3,4-Dimethyl-2,5-dioxo-4-(4-hydroxyphenyl)imidazolidin-1-yl]-2-(trifluorom ethyl)ben

164 as the free ligand 2-[[(3,5-di-tert-butyl-2-hydroxyphenyl)imino]methyl]-4,6-di-tert-butylphenol 1.

165 of 1-(4-(3,5-bis(benzo[d]thiazol-2-ylthio)-4-hydroxyphenyl) in the presence of p-toluenesulfinic acid

166 the level of incorporation of H-monomers (p-hydroxyphenyl) into cell walls.

167 4-Hydroxyphenyl isopropyl sulfone (6) is unreactive with e

168 G:S compositional bounds of normal plants; p-hydroxyphenyl levels are reported to reach a maximum of

169 el lignin consisting almost exclusively of p-hydroxyphenyl lignin subunits, and moreover exhibit subs

170 re directly derived from the precursors of p-hydroxyphenyl lignin, through the action of a dual speci

171 The half-component of TP2, i.e., 4,6-bis(4-hydroxyphenyl)-m-xylene (BX), deduced by simple structur

172 In this work, the CNT-mer entails a N-hydroxyphenyl maleimide functionality to be utilized in

173 AP metabolites, including S-(5-acetylamino-2-hydroxyphenyl)mercaptopyruvic acid (VI, formed by a Cys-

174 e NR4A1 antagonists 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) and a related p-carb

175 the TR3 antagonist 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) decreased proliferat

176 1,1-Bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) is a recently discov

177 2-chloro-4-phenylphenol, and bis(5-chloro-2-hydroxyphenyl)methane) antimicrobial agents found in bio

178 triclocarban, 0.372 muM for bis-(5-chloro-2-hydroxyphenyl)methane, 4.89 muM for 2-chloro-4-phenyl ph

179 yl]carbonyl]pentyl]amino]-1-[(3,5-d ibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3

180 yl]carbonyl]pentyl]amino]-1-[ (3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3

181 receptor inhibitor N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D-arginine-amide (BIBP3226) enhanc

182 nist BIBP3226 [(R)-N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D-arginine-amide], consistent with

183 1 inhibitor GW5074 (5-iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone) or the absence o

184 triphenylmethane-derivative (aurin; 4-[bis(p-hydroxyphenyl)methylene]-2,5-cyclohexadien-1-one) was id

185 tion of the aurone hispidol (6-hydroxy-2-[(4-hydroxyphenyl)methylidene]-1-benzofuran-3-one) as a majo

186 o groups to N-phenylpropyl-4beta-methyl-5-(3-hydroxyphenyl)morphan (4) led to compounds that were pur

187 antagonist N-phenylpropyl-4beta-methyl-5-(3-hydroxyphenyl)morphan (4) led to kappa selective pure op

188 ppa opioid receptor antagonist from the 5-(3-hydroxyphenyl)morphan class of opioids.

189 Several 4-(4-hydroxyphenyl)-N-arylhydantoins displayed partial agonis

190 Both of the enantiomers of 5-(3-hydroxyphenyl)-N-phenylethylmorphan with C9alpha-methyl,

191 ydroxy-2-dipropylaminotetralin to S-(-)-3-(3-hydroxyphenyl)-N-propylpiperidine, which is an agonist f

192 s that resulted in the aromatic-substituted (hydroxyphenyl)naphthol sulfonamides.

193 or the species-specific optimization of the (hydroxyphenyl)naphthols, a combinatorial approach was ap

194 ut predictably increased the proportion of p-hydroxyphenyl (P) units relative to the normally dominan

195 analogue, FEDPN (5-fluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl)pentanenitrile), has an 8.3-fold absolute

196 binant rat and human FAAH, we show that 5-(4-hydroxyphenyl)pentanesulfonyl fluoride (AM3506) has simi

197 t and selective FAAH inhibitor, AM3506 (5-(4-hydroxyphenyl)pentanesulfonyl fluoride).

198 ) possess in addition the rare 2-amino-5-(4'-hydroxyphenyl)pentanoic acid (Ahppa) and the novel 2-ami

199 On the other hand, modifications of the 3-hydroxyphenyl pharmacophore, but not the 7-hydroxy Tic p

200 addition manner to give a high yield of a 4-hydroxyphenyl phenyl(2,4,6-trimethylphenyl)phosphinite w

201 droxyphenyl)benzoic acid and 4-(5'-formyl-2'-hydroxyphenyl)phenyl propionic acid, respectively, in th

202 out by electrochemical oxidation of 1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone in the presence of

203 zazoles leading to the disubstituted 1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone.

204 of N-methyl and N-phenylpropyl 3-methyl-4-(3-hydroxyphenyl)piperazines (8a,b) gives (4a,b), which are

205 ly reported that N-substituted 3-methyl-4-(3-hydroxyphenyl)piperazines were a new class of opioid rec

206 of AT-076 (1), (R)-7-hydroxy-N-((S)-1-(4-(3-hydroxyphenyl)piperidin-1-yl)-3-methylbutan-2-yl)-1, 2,3

207 altrindole, and atrans-(3R,4R)-dimethyl-4-(3-hydroxyphenyl) piperidine (JDTic) are selective kappa op

208 of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (1) class of opioid receptor an

209 ned analogues of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (4) class of opioid receptor pu

210 r the antagonist activity observed in the (3-hydroxyphenyl)piperidine antagonists.

211 antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonist.

212 antagonist from the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of opioid antagonists.

213 r a mu ligand of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class to interact with the mu o

214 ,4R stereochemistry of the 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine core structure, the 3R attachme

215 n of the N-phenethyl trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine derivative 3, prototypical mu-o

216 rates that the N-substituted 3,4-dimethyl-(3-hydroxyphenyl)piperidine-derived antagonist, JDTic, reli

217 N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines (2a,b) are opioid receptor ant

218 ither axial or equatorial, similar to the (3-hydroxyphenyl)piperidines 4.

219 The series of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines have been widely investigated

220 concept wherein the (3R,4R)-3,4-dimethyl-4-(hydroxyphenyl)piperidinyl group represents the message,

221 ed, using as templates 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin and 5,10,15,20-tetrakis(3,5-dihy

222 ed by electropolymerization of N-(3-(4-(2-(4-hydroxyphenyl)propan-2-yl)phenoxy)propyl) 3-(5-hydroxy-1

223 eight bisphenol analogues, namely 2,2-bis(4-hydroxyphenyl)propane (BPA), 4,4'-(hexafluoroisopropylid

224 Bisphenol A (2,2-bis[4-hydroxyphenyl]propane, BPA), the monomer used to produce

225 ogenic methine on the photoproduct, rac-2-(p-hydroxyphenyl)propanoic acid (rac-9), is formed by closu

226 Mutremdamide A displays a rare 2-amino-3-(2-hydroxyphenyl)propanoic acid and a new N(delta)-carbamoy

227 e metabolism of catechin derivative and 3-(4-hydroxyphenyl)propanoic acid continued slowly for at lea

228 zed a fluoroethyl analogue of DPN (2,3-bis(4-hydroxyphenyl)propanonitrile), a known ERbeta-selective

229 sted 5-exo-dig reductive cyclization of 1-(2-hydroxyphenyl)-propargyl alcohols is achieved for 2-alky

230 UV-protective compounds such as 3-(3-hydroxyphenyl)propionate, apigenin, and naringenin, were

231 retion of the microbial-host cometabolite (3-hydroxyphenyl)propionate-sulfate and disrupted metabolit

232 These catabolites were 3-(3'-methoxy-4'-hydroxyphenyl)propionic acid, 3-(3'-hydroxy-4'-methoxyph

233 radation of the environmental pollutant 3-(3-hydroxyphenyl)propionic acid.

234 eport the synthesis of methyl esters of 3-(4-hydroxyphenyl)propionic, 3-(3,4-dihydroxyphenyl)propioni

235 yl)-4-propyl-1H-pyrazole (PPT) and 2,3-bis(4-hydroxyphenyl) propionitrile (DPN), respectively].

236 the ERbeta selective agonist DPN (2,3-bis (4-hydroxyphenyl) propionitrile) alone and in combination i

237 The ERbeta agonists 2,3-bis(4-hydroxyphenyl)-propionitrile and ERB041 also down-regula

238 ta, propylpyrazole triol (PPT) and 2,3-bis(4-hydroxyphenyl) proprionitrile (DPN), respectively, were

239 with the ER-beta selective agonist 2,2-bis(4-hydroxyphenyl)-proprionitrile (DPN), 17beta-estradiol (E

240 cha young wines were prone to contain higher hydroxyphenyl-pyranoanthocyanin concentrations.

241 sins (highest values for Syrah wines) and 10-hydroxyphenyl-pyranoanthocyanins (highest values for Mer

242 ected by disappearance during aging, whereas hydroxyphenyl-pyranoanthocyanins increased their contrib

243 e (via dehydrogenative homocoupling) or N-(o-hydroxyphenyl)pyrazole (via C-H oxygenation) or their mi

244 y dilute conditions (ca. 10 times) then N-(o-hydroxyphenyl)pyrazoles were the major or the sole produ

245 ion: see text] A variety of substituted 3-(2-hydroxyphenyl)pyridines have been prepared regioselectiv

246 nhibited the ability of MIF to tautomerize 4-hydroxyphenyl pyruvate.

247 genase (HPPD) catalyzes the conversion of (4-hydroxyphenyl)pyruvate (HPP) to homogentisate (HG).

248 catabolism of tyrosine, the conversion of (4-hydroxyphenyl)pyruvate (HPP) to homogentisate (HG).

249 Di- and triketone inhibitors of (4-hydroxyphenyl)pyruvate dioxygenase (HPPD) are both effec

250 (4-Hydroxy)mandelate synthase (HmaS) and (4-hydroxyphenyl)pyruvate dioxygenase (HPPD) are two alpha-

251 (4-Hydroxyphenyl)pyruvate dioxygenase (HPPD) catalyzes the

252 (4-hydroxyphenyl)pyruvate dioxygenase (HPPD) catalyzes the

253 (4-Hydroxyphenyl)pyruvate dioxygenase (HPPD) incorporates b

254 rom this organism the 4-hydroxyl group of (4-hydroxyphenyl)pyruvate is a requirement for catalysis; n

255 iron enzymes that use the same substrate, (4-hydroxyphenyl)pyruvate, but exhibit two different genera

256 tion of L-homotyrosine from acetyl-CoA and 4-hydroxyphenyl-pyruvate is found from the sequenced genom

257 ctivity using l-dopachrome methyl ester or 4-hydroxyphenyl pyruvic acid as substrates.

258 Mean N-4-hydroxyphenyl retinamide plasma level (day 7, steady-sta

259 We explored efficacy of N-(4-hydroxyphenyl) retinamide (4-HPR) and (-)-epigallocatech

260 udy examines the synergistic actions of N-(4-hydroxyphenyl) retinamide (4-HPR) and paclitaxel (PTX) t

261 We identify N-(4-hydroxyphenyl) retinamide (4-HPR) as effective in protec

262 N-(4-Hydroxyphenyl) retinamide (4-HPR) is a synthetic retinoi

263 ual disease with the cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide) may decre

264 nducer, such as arsenic trioxide (ARS), N-(4-hydroxyphenyl) retinamide (HPR) or dithiophene (NSC65624

265 N-(4-hydroxyphenyl) retinamide [4-HPR], a synthetic retinoid,

266 e retinoic acid derivative fenretinide (N-(4-hydroxyphenyl) retinamide; HPR) exerts therapeutic effec

267 The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR also known as fenretinid

268 e sensitivity of breast cancer cells to N-(4-hydroxyphenyl)retinamide (4-HPR) by suppressing nitric o

269 The synthetic retinoid fenretinide N-(4-hydroxyphenyl)retinamide (4-HPR) has shown promise for t

270 cytotoxicity of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) in tumor cells.

271 The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) induces apoptosis in a

272 N-(4-Hydroxyphenyl)retinamide (4-HPR), a dihydroceramide synt

273 n with low micromolar concentrations of N-(4-hydroxyphenyl)retinamide (4-HPR), which downmodulates cy

274 ation of pharmacological agents such as N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), by treatm

275 g the major metabolites of 4-HPR, 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) showed the highes

276 The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) has shown potential as a

277 N-(4-hydroxyphenyl)retinamide (4HPR), a synthetic retinoid ef

278 N-(4-hydroxyphenyl)retinamide (HPR) potently and reversibly r

279 N-(4-Hydroxyphenyl)retinamide up-regulated ELF3, c-Jun, Rb2/p

280 henyl]-2-naphthalene carboxylic acid or N-(4-hydroxyphenyl)retinamide.

281 However, N-(4-hydroxyphenyl)-retinamide, another apoptosis-inducing re

282 Order parameters of the hydroxyphenyl ring determined by the 1H-13C DIPSHIFT exp

283 as 1H NMR cross-relaxation rates, locate the hydroxyphenyl ring of the ligand near the lipid glycerol

284 essentially hydrophobic environment of its p-hydroxyphenyl site and the absence of direct hydrogen bo

285 A related dye, 2,4-bis(4-(N,N-dimethyl)-2-hydroxyphenyl)squaraine (1-1OHSQ), at similar coverages

286 ates three key features: (a) a bis(4-amino-3-hydroxyphenyl)squaraine core with bright deep-red fluore

287 6a-g can exist in conformations where the 3-hydroxyphenyl substituent is either axial or equatorial,

288 Products containing a 2-(2'-hydroxyphenyl) substituent undergo excited state intramo

289 avylium salts substituted at 4-position with hydroxyphenyl substituents were synthesized by acidic co

290 tions with GLY300, observed for the potent 4-hydroxyphenyl substituted inhibitors.

291 ted binding orientation of the 3,5-dibromo-4-hydroxyphenyl substructure and revealed a strong prefere

292 e of two alpha-phenyls, so that benzhydryl 4-hydroxyphenyl sulfone (8) is readily alpha-halogenated i

293 f the 5-HT(7) receptor antagonist (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2 -(2-(4-methyl-1-piperidinyl)et

294 ing lignin to a 10-fold higher fraction of p-hydroxyphenyl units at the expense of syringyl units.

295 in content, and preferential accumulation of hydroxyphenyl units in lignin, indicating that the CSE e

296 ced lignin deposition, increased levels of p-hydroxyphenyl units in the lignin polymer, and a relativ

297 Benzoic acid (38.4mug/ml), 4-hydroxy-5-(3'-hydroxyphenyl)-valeric acid (26.2mug/ml) and phenylaceti

298 hydrolyzed by the esterase CA activity to 2-hydroxyphenyl-vinylsulfonic acids, which thereafter bind

299 1-(4-(3,5-Bis(benzo[d]thiazol-2-ylthio)-4-hydroxyphenyl) was converted into 2-(benzo[d]thiazol-2-y

300 The contributions of p-hydroxyphenyls were generally similar to the guaiacyl so